Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis.Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB)
Source: Neurology and Therapy - Category: Neurology Source Type: research